Remission of hepatocellular carcinoma with arginine depletion induced by systemic release of endogenous hepatic arginase due to transhepatic arterial embolisation, augmented by high-dose insulin: Arginase as a potential drug candidate for hepatocellular carcinoma

Cancer Letters

Volumn 224, Issue 1, 2005, Pages 67-80

  Cheng, P N M ^a,b   Leung, Y C ^a   Lo, W H ^a   Tsui, S M ^a   Lam, K C ^b  

^a HONG KONG POLYTECHNIC UNIVERSITY   (Hong Kong)

^b HONG KONG SANATORIUM AND HOSPITAL   (Hong Kong)

Author keywords

Arginase; Arginine depletion; Auxotrophic; Hepatocellular carcinoma; High dose insulin infusion; Transhepatic arterial embolisation

Indexed keywords

ARGINASE; ARGININE; GELFOAM; INSULIN; IODINATED POPPYSEED OIL;

ADULT; ADVANCED CANCER; AGED; AMINO ACID BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; ARTIFICIAL EMBOLISM; BONE METASTASIS; CANCER REGRESSION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MEGADOSE; ENZYME ACTIVITY; ENZYME RELEASE; FEMALE; HEPATIC ARTERY; HUMAN; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; PRIORITY JOURNAL;

ADULT; AGED; ARGINASE; ARGININE; CARCINOMA, HEPATOCELLULAR; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

BACTERIA (MICROORGANISMS); MYCOPLASMA;

EID: 19344365089     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.10.050     Document Type: Article

References (32)

1. D.N. Wheatley, and E. Campbell Arginine catabolism, liver extracts and cancer Pathol. Oncol. Res. 8 2002 18 25
2. A. Barbul Arginine: biochemistry, physiology, and therapeutic implications JPEN J. Parenter. Enteral. Nutr. 10 1986 227 238
3. G. Wu, and S.M. Morris Jr Arginine metabolism: nitric oxide and beyond Biochem. J. 15 1998 1 17
4. N. Hoogenraad, N. Totino, H. Elmer, C. Wraight, P. Alewood, and R.B. Johns Inhibition of intestinal citrulline synthesis causes severe growth retardation in rats Am. J. Physiol. 249 1985 G792 G799
5. R.T. Schimke Enzymes of arginine metabolism in mammalian cell culture. I. Repression of argininosuccinate synthetase and argininosuccinase J. Biol. Chem. 239 1964 136 145
6. L. Scott, J. Lamb, S. Smith, and D.N. Wheatley Single amino acid (arginine) deprivation: rapid and selective death of cultured transformed and malignant cells Br. J. Cancer 83 2000 800 810
7. J.M. Storr, and A.F. Burton The effects of arginine deficiency on lymphoma cells Br. J. Cancer 30 1974 50 59
8. K.V. Savoca, F.F. Davis, T. van Es, J.R. McCoy, and N.C. Palczuk Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia Cancer Biochem. Biophys. 7 1984 261 268
9. J.M. Harris, N.E. Martin, and M. Modi Pegylation: a novel process for modifying pharmacokinetics Clin. Pharmacokinet. 40 2001 539 551
10. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat. Rev. Drug Discov. 2 2003 214 221
11. I. Lieberman, and P. Ove Inhibition of growth of cultured mammalian cells by liver extracts Biochim. Biophys. Acta 38 1960 153
12. S.J. Bach, and D. Swaine The effect of arginase on the retardation of tumour growth Br. J. Cancer 19 1965 379 386
13. R.W. Holley Evidence that a rat liver 'inhibitor' of the synthesis of DNA in cultured mammalian cells is arginase Biochim. Biophys. Acta 145 1967 525 527
14. J.A. Nelson, J.W. Carpenter, and H.P. Morris Growth inhibitory and arginase activities in liver and hepatoma extracts Proc. Soc. Exp. Biol. Med. 149 1975 900 902
15. H. Terayama, T. Koji, M. Kontani, and T. Okumoto Arginase as an inhibitory principle in liver plasma membranes arresting the growth of various mammalian cells in vitro Biochim. Biophys. Acta 720 1982 188 192
16. B.J. Dillon, F.W. Holtsberg, C.M. Ensor, J.S. Bomalaski, and M.A. Clark Biochemical characterization of the arginine degrading enzymes arginase and arginine deiminase and their effect on nitric oxide production Med. Sci. Monit. 8 2002 BR248 BR253
17. M. Ikemoto, S. Tsunekawa, M. Awane, Y. Fukuda, H. Murayama, and M. Igarashi A useful ELISA system for human liver-type arginase, and its utility in diagnosis of liver diseases Clin. Biochem. 34 2001 455 461
18. M. Ikemoto, S. Tsunekawa, Y. Toda, and M. Totani Liver-type arginase is a highly sensitive marker for hepatocellular damage in rats Clin. Chem. 47 2001 946 948
19. M. Kimura, K.I. Tatsumi, H. Tada, M. Ikemoto, Y. Fukuda, and A. Kaneko Amino N, enzyme immunoassay for autoantibodies to human liver-type arginase and its clinical application Clin. Chem. 46 2000 112 117
20. M. Ikemoto, S. Tsunekawa, K. Tanaka, A. Tanaka, Y. Yamaoka, and K. Ozawa Liver-type arginase in serum during and after liver transplantation: a novel index in monitoring conditions of the liver graft and its clinical significance Clin. Chim. Acta 271 1998 11 23
21. H. Wakabayashi, T. Ushiyama, K. Ishimura, K. Izuishi, Y. Karasawa, and T. Masaki Significance of reduction surgery in multidisciplinary treatment of advanced hepatocellular carcinoma with multiple intrahepatic lesions J. Surg. Oncol. 82 2003 98 103
22. M. Ryu, Y. Shimamura, T. Kinoshita, M. Konishi, N. Kawano, and M. Iwasaki Therapeutic results of resection, transcatheter arterial embolization and percutaneous transhepatic ethanol injection in 3225 patients with hepatocellular carcinoma: a retrospective multicenter study Jpn. J. Clin. Oncol. 27 1997 251 257
23. P.W. Pisters, E. Cersosimo, A. Rogatko, and M.F. Brennan Insulin action on glucose and branched-chain amino acid metabolism in cancer cachexia: differential effects of insulin Surgery 111 1992 301 310
24. S. Tepic, P. Pyk, Therapeutic compositions for treatment of cancer, PCT Patent, No. WO 98/06421, 19 Feb 1998.
25. H. Takaku, M. Takase, S. Abe, H. Hayashi, and K. Miyazaki In vivo anti-tumor activity of arginine deiminase purified from Mycoplasma arginini Int. J. Cancer 51 1992 244 249
26. K. Sugimura, S. Fukuda, Y. Wada, M. Taniai, M. Suzuki, and T. Kimura Identification and purification of arginine deiminase that originated from Mycoplasma arginini Infect. Immun. 58 1990 2510 2515
27. F. Izzo, P. Marra, G. Beneduce, G. Castello, P. Vallone, and V. de Rosa Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies J. Clin. Oncol. 22 2004 1815 1822
28. S.A. Curley, J.S. Bomalaski, C.M. Ensor, F.W. Holtsberg, and M.A. Clark Regression of hepatocellular cancer in a patient treated with arginine deiminase Hepatogastroenterology 50 2003 1214 1216
29. H. Takaku, S. Misawa, H. Hayashi, and K. Miyazaki Chemical modification by polyethylene glycol of the anti-tumor enzyme arginine deiminase from Mycoplasma arginini Jpn. J. Cancer Res. 84 1993 1195 1200
30. H. Takaku, M. Matsumoto, S. Misawa, and K. Miyazaki Anti-tumor activity of arginine deiminase from Mycoplasma argini and its growth-inhibitory mechanism Jpn. J. Cancer Res. 86 1995 840 846
31. R. Philip, E. Campbell, and D.N. Wheatley Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures Br. J. Cancer 88 2003 613 623
32. C.M. Ensor, F.W. Holtsberg, J.S. Bomalaski, and M.A. Clark Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo Cancer Res. 62 2002 5443 5450